ALK-targeted therapy for poor-prognosis childhood cancers

The Lancet Oncology

Volumn 14, Issue 6, 2013, Pages 439-440

  Moreno, Lucas ^a,b  

^a Structural Biology and Biocomputing Programme   (Spain)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ALK GENE; ANTINEOPLASTIC ACTIVITY; CANCER PROGNOSIS; CHILDHOOD CANCER; DRUG EFFICACY; DRUG SAFETY; HUMAN; LARGE CELL LYMPHOMA; LETTER; LUNG NON SMALL CELL CANCER; NEUROBLASTOMA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES;

EID: 84876973058     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70123-2     Document Type: Letter

References (10)

1. Mossé YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol 2013, published online April 16. http://dx.doi.org/10.1016/S1470-2045(13)70095-0.
2. George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008, 455:975-978.
3. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 455:971-974.
4. Janoueix-Lerosey I, Lequin D, Brugières L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008, 455:967-970.
5. Mossé YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455:930-935.
6. Matthay KK, George RE, Yu AL Promising therapeutic targets in neuroblastoma. Clin Cancer Res 2012, 18:2740-2753.
7. Berry T, Luther W, Bhatnagar N, et al. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell 2012, 22:117-130.
8. Heukamp LC, Thor T, Schramm A, et al. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Sci Transl Med 2012, 4:141ra91.
9. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
10. Kim A, Fox E, Warren K, et al. Characteristics and outcome of pediatric patients enrolled in phase I oncology trials. Oncologist 2008, 13:679-689.